Pharmaceuticals
ASTRUM-005: Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of Serplulimab at ASCO 2022
SHANGHAI, June 6, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that an international randomized phase 3 study (ASTRUM-005) of HANSIZHUANG (serplulimab), an anti-PD-1 mAb independently developed by Henlius, as first-line treatment for extensive-stage small-cell lung can...
2022-06-06 21:00
2114
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022
SHANGHAI, June 6, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual M...
2022-06-06 20:50
2732
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...
2022-06-06 12:23
2001
Akeso releases promising data of Ivonescimab (PD-1/VEGF BsAbs, AK112) for advanced NSCLC at ASCO 2022
HONG KONG, June 5, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, released clinical details in poster presentation featuring phase Ib...
2022-06-06 09:00
1528
Akeso announces oral presentation featuring promising clinical data of Cadonilimab (PD-1/CTLA-4 BsAbs, AK104) for the first-line treatment of R/M cervical cancer at ASCO 2022
HONG KONG, June 5, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, released updated results of Cadonilimab (PD-1/CTLA-4 Bispecific, AK...
2022-06-06 09:00
1360
KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
SYDNEY, June 3, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The data is the subj...
2022-06-03 19:00
8473
Sanyou Super-Trillion Innovative Antibody Drug Discovery Platform Announced - World Premiere
SHANGHAI, June 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals officially
launched STAL (Super-Trillion Antibody Libraries) onJune 3, 2022, which is a
super-trillion innovative antibody drug discovery platform of Sanyou's own
intellectual property.
2022-06-03 08:00
2260
ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic
- Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into preclinical development and further strengthen/expand innovative technology platforms - Build vertically integrated internal capabilities for more efficient drug development WOODINVILLE, Wash. and SUZHOU, China...
2022-06-02 20:00
2332
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profound disability MELBOURNE, Australia, June 2, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disea...
2022-06-02 20:00
2253
First AI to Refine Medical Coding by Exploring Therapeutic Data
SAN FRANCISCO, June 1, 2022 /PRNewswire/ -- Medical AI start-up Aesop
Technology announced a new partnership that made their new product,DxPrime
2022-06-02 01:22
2477
Standigm Signs MOU with Merck Korea for AI drug Discovery Research
- Merck's retrosynthesis AI software SYNTHIA™ accelerates Standigm's synthesis capability SEOUL, South Korea, June 1, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Und...
2022-06-01 21:00
2149
QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings
SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders, today announced that its Q-1802 clinical program was se...
2022-05-31 22:30
1917
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the completion of patient enrollment in a Phase 3 clinica...
2022-05-31 20:00
1496
Illuccix® Granted Transitional Pass-Through Payment Status
INDIANAPOLIS, May 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of gallium Ga 68 gozetotide injection) has been granted Transitional Pass-Through Payment Status by the U.S...
2022-05-31 19:00
1159
Latest Results from AENEAS Study of Hansoh Pharma's Ameile® Published in Top International Academic Journal JCO
SHANGHAI, May 31, 2022 /PRNewswire/ -- Recently, the Journal of Clinical Oncology (JCO, IF:44.544), an internationally renowned oncology journal, published an online paper on the AENEAS study of Ameile® (Aumolertinib Mesylate Tablets, an innovative drug developed by Hansoh Pharma), which was led ...
2022-05-31 17:56
624
AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease
SHANGHAI, May 30, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announces that the first patient has been dosed in its US Phase 1 st...
2022-05-31 11:30
1381
Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists
Preclinical Studies on the Potential Application of Transcenta's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Androgen Receptor-Negative/Low Prostate Cancer SUZHOU, China, May 30, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage bio...
2022-05-31 08:08
1215
InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer
NANJING, China, May 29, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label...
2022-05-30 08:10
1661
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting
BEIJING, SHANGHAI and BOSTON, May 27, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) fr...
2022-05-28 00:22
5988
Asieris to present a study protocol of APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy（NAC）for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting
SHANGHAI, May 27, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases announced that ANTICIPATE Study will be presented at the...
2022-05-27 22:16
2785
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 289 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 253 media titles]
2024-04-30 15:13Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
12314
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
7944
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
7544
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
7480
